New eye drug shows promise for blinding disease

NCT ID NCT06164587

First seen Jan 11, 2026 · Last updated May 15, 2026 · Updated 20 times

Summary

This early-stage study tests a new drug called Kamuvudine-8 (K8) for people with geographic atrophy, an advanced form of age-related macular degeneration that causes vision loss. About 30 participants will receive eye injections of K8 and be monitored for 26 weeks to check safety and whether it slows the growth of damaged areas in the eye. The goal is to see if this treatment can help control the disease and preserve sight.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Hilton Head Retina Institute

    Hilton Head, South Carolina, 29926-2277, United States

  • Loma Linda University

    Loma Linda, California, 92354, United States

  • Ophthalmology LTD

    Sioux Falls, South Dakota, 57108, United States

  • Oregon Eye Consultants, Cascade Medical Research

    Eugene, Oregon, 97401, United States

  • Southeastern Retina Associates

    Hixson, Tennessee, 37343, United States

  • Southeastern Retina Associates

    Bristol, Virginia, 24201, United States

  • The Maine Eye Center

    Portland, Maine, 04101, United States

  • University of Kentucky Advanced Eye Care

    Lexington, Kentucky, 40508, United States

  • Vistar Eye Center

    Roanoke, Virginia, 24019, United States

Conditions

Explore the condition pages connected to this study.